Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Lepodisiran · LY3819469

Oligonucleotide (siRNA) · developed by ELI LILLY &

Phase 3 Most advanced trial

LLY Developer

1 Registered trials

What is Lepodisiran?

Lepodisiran is a small interfering RNA (siRNA) oligonucleotide that targets LPA, the gene encoding apolipoprotein(a), to lower its production. It is studied in atherosclerosis and cardiovascular disease in people with elevated lipoprotein(a).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: LY3819469
Drug type: Oligonucleotide (siRNA)
Therapy area: Cardiovascular
Developer: ELI LILLY & (LLY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: X4BE7S8PN9

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07613294	Phase 3	Atherosclerosis	Recruiting	LLY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AtherosclerosisCardiovascular DiseasesLipoprotein(a)

More from ELI LILLY &

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Mirikizumab FDA approved Orforglipron FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3

Follow LLY, the company behind Lepodisiran

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z